ArticleBiological procedures online2025
Anti-CD133-grafted single-walled carbon nanotubes as doxorubicin carrier.
Article in Biological procedures online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bridging solubility, stability, and translation: advances in carbon nanotube-based drug delivery systems.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvances in nanomedicine have spurred interest in antibody-conjugated carbon nanotubes for targeted cancer therapy. CD133, a marker enriched in chemoresistant cancer stem cells, presents a strategic target for precision drug delivery. This study explores functionalized single-walled carbon nanotubes (SWCNTs) as dual-action platforms for enhanced doxorubicin (DXR) delivery and CD133-specific targeting.
methodsTwo nano formulations-SWCNT-Ab/DXR (antibody-functionalized) and SWCNT-PEG-Ab/DXR (pegylated antibody-functionalized)-were engineered to encapsulate DXR. Release profiles, cytotoxicity, and apoptosis were assessed in CD133
resultsPEGylation markedly enhanced colloidal stability and drug-loading capacity, with SWCNT-PEG-Ab/DXR achieving 92% DXR encapsulation vs. 78% for non-PEGylated counterparts. In vitro, the PEGylated system showed amplified cytotoxicity (IC50: 2.1 µM vs. 3.8 µM for SWCNT-Ab/DXR) and 1.7-fold higher apoptosis induction in HT-29 cells. Computational data aligned with experimental findings: DXR adsorption energy was strongest on PEG-NH
conclusionsBy integrating PEG-mediated stealth properties, charge-modified surfaces, and antibody targeting, SWCNT-PEG-Ab/DXR emerges as a multifunctional nanoplatform with enhanced tumor selectivity and therapeutic payload delivery. This dual experimental-computational approach underscores the potential of rationally engineered nanotubes to overcome limitations in conventional chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.